Brian Ball

1.7k total citations
45 papers, 1.0k citations indexed

About

Brian Ball is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Brian Ball has authored 45 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 24 papers in Molecular Biology and 13 papers in Genetics. Recurrent topics in Brian Ball's work include Acute Myeloid Leukemia Research (33 papers), Histone Deacetylase Inhibitors Research (13 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Brian Ball is often cited by papers focused on Acute Myeloid Leukemia Research (33 papers), Histone Deacetylase Inhibitors Research (13 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Brian Ball collaborates with scholars based in United States, Germany and France. Brian Ball's co-authors include Benjamin L. Ebert, Michael G. Kharas, D. Gary Gilliland, Steven Lane, Fátima Al‐Shahrour, Mahnaz Paktinat, Rachel Okabe, Thomas Mercher, Ann Mullally and Thomas Prébet and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Brian Ball

42 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Ball United States 14 625 576 397 141 115 45 1.0k
Mahnaz Paktinat United States 6 616 1.0× 432 0.8× 337 0.8× 138 1.0× 110 1.0× 8 929
YinWei Ho United States 10 608 1.0× 530 0.9× 263 0.7× 262 1.9× 96 0.8× 14 1.1k
Chung Hoow Kok Australia 17 338 0.5× 454 0.8× 245 0.6× 153 1.1× 116 1.0× 68 800
Mauro Nanni Italy 16 402 0.6× 456 0.8× 294 0.7× 86 0.6× 103 0.9× 43 804
J. Erika Haydu United States 8 405 0.6× 407 0.7× 289 0.7× 123 0.9× 85 0.7× 12 799
Eri Kawata Japan 14 279 0.4× 455 0.8× 327 0.8× 188 1.3× 134 1.2× 42 842
Vera Magistroni Italy 13 336 0.5× 408 0.7× 295 0.7× 146 1.0× 44 0.4× 23 783
Annamaria Galietta Italy 6 434 0.7× 441 0.8× 309 0.8× 143 1.0× 48 0.4× 8 836
Cristi Gidel United States 7 681 1.1× 620 1.1× 360 0.9× 264 1.9× 112 1.0× 7 1.0k

Countries citing papers authored by Brian Ball

Since Specialization
Citations

This map shows the geographic impact of Brian Ball's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Ball with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Ball more than expected).

Fields of papers citing papers by Brian Ball

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Ball. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Ball. The network helps show where Brian Ball may publish in the future.

Co-authorship network of co-authors of Brian Ball

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Ball. A scholar is included among the top collaborators of Brian Ball based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Ball. Brian Ball is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeidan, Amer M., Anthony S. Stein, Johanna Rimpiläinen, et al.. (2025). Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study. Blood. 146(Supplement 1). 236–236. 1 indexed citations
2.
Chin, Kuo‐Kai, Brian Ball, Yasmin Abaza, et al.. (2025). Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. Blood Advances. 10(5). 1537–1547.
3.
Ngo, Dat, Shanpeng Li, Joycelynne Palmer, et al.. (2024). Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib. Leukemia & lymphoma. 65(3). 372–377. 2 indexed citations
4.
Shimony, Shai, Jan Philipp Bewersdorf, Rory M. Shallis, et al.. (2024). Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 38(4). 762–768. 17 indexed citations
5.
6.
Stein, Anthony S., Jianying Zhang, Lucy Ghoda, et al.. (2024). Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 4264–4264. 1 indexed citations
7.
Chen, Andrew, et al.. (2023). CDK9 Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma (MCL). Blood. 142(Supplement 1). 1641–1641. 1 indexed citations
8.
Rosa, Corinna La, Ibrahim Aldoss, Dongyun Yang, et al.. (2023). CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients after Stem Cell Transplant. Transplantation and Cellular Therapy. 29(2). S68–S69. 1 indexed citations
9.
10.
11.
Sun, Duanchen, Daniel J. Coleman, Tingting Liu, et al.. (2023). CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. Molecular Cancer. 22(1). 64–64. 23 indexed citations
12.
Ball, Brian, Paul Koller, & Vinod Pullarkat. (2022). Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia. Current Opinion in Oncology. 34(5). 531–539. 3 indexed citations
13.
Komrokji, Rami S., Najla Al Ali, Onyee Chan, et al.. (2021). Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia & lymphoma. 63(1). 199–204. 2 indexed citations
14.
15.
Jain, Akriti, Madelyn Burkart, Christopher Famulare, et al.. (2021). Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 32–32. 13 indexed citations
16.
17.
Ball, Brian, Meier Hsu, Sean M. Devlin, et al.. (2019). RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy. Blood. 134(Supplement_1). 18–18. 13 indexed citations
18.
Kharas, Michael G., Christopher J. Lengner, Fátima Al‐Shahrour, et al.. (2010). Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. DSpace@MIT (Massachusetts Institute of Technology). 2 indexed citations
19.
Koo, Sun Hoe, Brian J.P. Huntly, Yuan Wang, et al.. (2010). Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica. 95(10). 1642–1650. 13 indexed citations
20.
Mullally, Ann, Steven Lane, Brian Ball, et al.. (2010). Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. Cancer Cell. 17(6). 584–596. 285 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mahnaz Paktinat Breakdown of academic impact, for papers by YinWei Ho Breakdown of academic impact, for papers by Chung Hoow Kok Breakdown of academic impact, for papers by Mauro Nanni Breakdown of academic impact, for papers by J. Erika Haydu Breakdown of academic impact, for papers by Eri Kawata Breakdown of academic impact, for papers by Vera Magistroni Breakdown of academic impact, for papers by Annamaria Galietta Breakdown of academic impact, for papers by Cristi Gidel
Rankless by CCL
2026